Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
NFATC2IP antisense RNA 1 (NFATC2IP-AS1) is a long non-coding RNA (lncRNA) gene located antisense to the NFATC2IP (Nuclear Factor of Activated T Cells 2 Interacting Protein) coding gene[1]. As a non-coding RNA, NFATC2IP-AS1 does not encode a protein and its primary molecular function is presumed to be the regulation of its sense partner (NFATC2IP) or other genomic loci via RNA-mediated mechanisms such as transcriptional interference, RNA-DNA, or RNA-protein interactions[1]. There is no evidence it serves as a direct therapeutic target, biomarker, or has established roles in disease pathogenesis. Its biological role remains largely uncharacterized, with potential involvement in the regulation of protein-coding gene expression. Key notes for structured data extraction and curation: - "NFATC2IP antisense RNA 1" is not a receptor, enzyme, transporter, or canonical therapeutic target; it is a long non-coding RNA[1]. - No reported interacting drugs or mechanisms of drug action, nor is it recognized as a disease biomarker in currently available literature[1]. - While the NFATC2IP protein-coding gene has biological relevance in genome integrity and SUMOylation responses[2][6], these functions do not apply to the non-coding antisense transcript (NFATC2IP-AS1). If you intended the *protein-coding* NFATC2IP, distinct from the antisense RNA, please clarify, as this would require a different annotation (molecular class: protein, biological function: DNA repair, etc.)[2][4][6].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on NFATC2IP antisense RNA 1 (NFATC2IP-AS1).